SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media is trending amid renewed discussions around the release of Epstein files and their potential implications for Donald Trump. The community is actively debating the significance of newly released emails and their connection to Trump, with some questioning his past associations and others dismissing the concerns as politically motivated. Broader conversations encompass topics like digital IDs, the economy, and the influence of political figures.

United States Antimony Corp. engages in the extraction, processing and sale of antimony, zeolite, silver, and gold products. It operates through the following segments: United States Antimony Operations, Mexican Antimony Operations, Precious Metals Recovery, and United States Zeolite Operations. The company was founded by John C. Lawrence in June 1968 and is headquartered in Thompson Falls, MT.

United States Antimony Corp.

United States Antimony Corp

UAMY is trending as investors digest mixed signals from earnings, including strong revenue growth but a Q3 miss, while also weighing future government contracts and the significance of antimony in critical minerals. The community is actively discussing the potential for future growth, the impact of government funding, and the company's strategic positioning amidst global supply chain concerns. Bullish sentiment remains, centered around long-term prospects and UAMY's role in securing domestic mineral supply.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax ($NVAX) is trending due to Shah Capital's renewed push for a company sale, citing dissatisfaction with management's performance and capital allocation, leading to investor concerns about operational inefficiencies. The community is discussing potential proxy fights and expressing frustration with the lack of communication from Novavax leadership regarding a potential deal or partnership. Investors are also weighing the potential of Novavax's Matrix-M adjuvant technology and upcoming catalysts, such as Sanofi partnership milestones, against ongoing concerns about cash burn and potential dilution.

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

ORCL is trending downwards, driven by investor concerns around debt financing for AI infrastructure and recent analyst downgrades. Community sentiment is largely bearish, with discussions focusing on the lack of management response to the stock's decline and speculation about a potential AI bubble. Some traders are looking for a potential bounce, while others are questioning the company's valuation and future prospects.

Korro Bio, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of a new class of genetic medicines based on editing RNA. The company was founded by Nessan Bermingham, Jean-Francois B. Formela, Joshua Rosenthal, and Andrew Fraley in 2018 and is headquartered in Cambridge, MA.

Korro Bio Inc.

Korro Bio (KRRO) is trending amid discussions around its recent stock performance and potential opportunities, following a significant drop. Bullish investors are eyeing potential bounce plays, citing institutional ownership and cash reserves, while others point to risk factors from the latest 10-Q filing and pivot in R&D.

Cisco Systems, Inc. engages in the design, manufacture, and sale of Internet Protocol-based networking products and services related to the communications and information technology industry. The firm operates through the following geographical segments: the Americas, EMEA, and APJC. Its products include the following categories: Secure, Agile Networks, Internet for the Future, Collaboration, End-to-End Security, Optimized Application Experiences, and Other Products. The company was founded by Sandra Lerner and Leonard Bosack in 1984 and is headquartered in San Jose, CA.

Cisco Systems, Inc.

Cisco's earnings beat and raised guidance are driving community discussion, with some seeing it as a pure technical breakout while others question if the numbers warrant the move. Investors are debating the company's AI prospects and its potential to capitalize on the AI datacenter buildout, with some drawing parallels to the dot-com era boom and bust.

Draganfly, Inc. engages in the manufacture and sale of commercial unmanned aerial vehicle systems and software serving the public safety, agriculture, industrial inspections, security, mapping, and surveying markets. Its products include quad-copters, fixed wing aircrafts, ground based robots, hand held controllers, and software used for tracking, live streaming, and data collection. The firm also offers custom engineering, training, simulation consulting, as well as data and flight training services. The company was founded by Zenon Dragan and Christine Dragan in 1998 and is headquartered in Saskatoon, Canada.

Draganfly Inc

Draganfly (DPRO) is trending amid discussions about a new partnership and its participation in the AUSA Annual Meeting & Exposition. The community is actively discussing the company's potential in the defense sector, especially regarding drone technology for the U.S. Army, as well as speculation about the impact of new contracts on revenue growth and profitability.

SSgA Active Trust - SPDR S&P 500 ETF Trust

SPY is trending amid government shutdown vote anticipation and the potential release of Epstein files, leading to market uncertainty. The community is discussing potential outcomes, including a 'sell the news' event if the government reopens, and the impact of missing economic data. Sector rotation out of tech and precious metals potentially signaling economic concerns are also being debated.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

CorMedix is trending as investors discuss its recent earnings and future prospects, with community members highlighting revenue growth while also expressing concerns about potential dilution and the impact of TDAPA (Transitional Drug Add-on Payment Adjustment) policy changes in 2026. A point of discussion is the company's strategic investments, particularly its stake in Talphera (TLPH) and their kidney treatment Niyad, along with speculation about potential acquisitions and the influence of institutional investors like Deerfield.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MLTX is trending as investors discuss recent institutional buying and upcoming catalysts, including a December FDA meeting and presentations at the NYC Inflammatory Skin Disease Summit. The community is bullish, noting the high level of institutional ownership and potential for a short squeeze. Some are speculating about a potential buyout and comparing MLTX to other successful biotech companies.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

BELLUS Health is focused on developing drugs for rare diseases, starting with conditions that affect the kidneys. The lead program KIACTAâ?¢, a novel drug candidate, is in data review after announcing on June 20, 2016 top-line results from its Phase 3 study for the treatment of AA amyloidosis, a rare disease resulting in renal dysfunction that often leads to dialysis and death. BELLUS Health is partnered with global private equity firm Auven Therapeutics for the development of KIACTAâ?¢. KIACTAâ?¢ is also being developed as a treatment in a second indication called sarcoidosis, a rare, potentially fatal inflammatory condition that affects the lungs. An investigational new drug application (IND) for a Phase 2/3 clinical study is expected to be filed with the U.S. Food and Drug Administration in 2016. In addition, BELLUS Health is developing Shigamabâ?¢, an antibody treatment for Hemolytic Uremic Syndrome caused by Shiga toxin-producing E. coli (sHUS). sHUS often leads to dialysis, chronic kidney disease and in some cases death, particularly in children. Shigamabâ?¢ pre-clinical studies for the treatment of sHUS are currently underway.  BELLUS Healthâ??s pipeline also includes a research-stage project for the treatment of AL amyloidosis, a rare disease in which amyloid protein builds up and causes dysfunction in various parts of the body.

Bellus Health Inc

Will NVIDIA ($NVDA) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

) beat quarterly earnings? 
 
*Powered by Polymarket

Fiscal Period	Estimated	Reported	Surprise	Result
Q2 '23	-$0.21	--	--	N/A
Q1 '23	-$0.19	-$0.20	-5.26%	MISSED

BLU
Bellus Health Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q1 '23

Historical Earnings

Latest BLU News

BLUBellus Health Inc